Indication intelligence, analysis and sector perception

Alnylam Pharmaceuticals (ALNY) reports Q1/2022 earnings; net loss and net product revenue and collaboration decreases

April 28, 2022 11:56am

ALNY is down -$15.40 or -9.94% to $139.52 – so far and fluctuating

Net loss was -$234.34 M or -$2.00 per share as compared to Q1/21’s $200.29 M or -$1.71 per share, while the cash position was $2.24 B

Revenue was $137 M, a -10% decrease compared to Q4/21.

Net product revenues increased 38% compared to Q1/21, net revenues from collaborations decreased 38% compared to the first quarter of 2021, primarily due to a decrease in revenue from its collaboration with Regeneron.

GAAP R&D expenses decreased compared to Q1/21, SG&A increased compared to Q1/21.

This quarterly report represents an earnings surprise of -3.63%. A quarter ago, it was expected that this RNA interference drug developer would post a loss of $1.47 per share when it actually produced a loss of $2.16, delivering a surprise of -46.94%. <Zacks>

ALNY shares have lost about 8.6% since the beginning of the year

Over the last four (4) quarters, ALNY has not been able to surpass consensus EPS estimates.

Guidance: The current consensus EPS estimate is -$1.69 on $276.05 M in revenues for the coming quarter and -$6.92 on $1.15 B in revenues for the 2022. <Zacks>

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.